Quotient Sciences invests in new drug substance manufacturing facility


Project will center on equipment and technology improvements, says UK R&D and manufacturing accelerator

Quotient Sciences, a drug development and manufacturing accelerator, has invested $8.7 million in its recently acquired manufacturing facility in Alnwick, UK. The financial commitment will grow Quotient’s drug substance manufacturing capability and is expected to create 80 new jobs over the next three years.

The investment will repurpose a 16,100 square-foot-plus footprint and will feature additional equipment and technology.

The aforementioned additional equipment will consist of advances in digital control and data capture, certifying transfer from laboratory to multi-kilo scale production. Further, processing equipment with new developments in modular continuous technology will maximize responsiveness and agility for manufacturing processes, the company says.

Back in February, Quotient purchased the Alnwick facility from Arcinova with the goal of expanding its portfolio to include drug substance, drug product and clinical testing skills all under one organization. The latest deal allows Quotient to support customers with an “end-to-end” offering, from candidate selection, all the way through commercial product launch.

“Following our integration into Quotient Sciences earlier in the year, it is tremendously exciting to see the Alnwick facility continue to expand capabilities as we move into larger scale and commercial manufacturing,” says Roger Kilburn, Quotient Sciences’ senior vice president of candidate development services. “Science and agility are at the core of Quotient Sciences, and our team strives to innovate and develop smarter approaches to process R&D for our customers and drive the adoption of continuous processing technologies.”

Related Videos
© 2024 MJH Life Sciences

All rights reserved.